FindTrial
Sign In

Retrospective study of TACE combined immune checkpoint inhibitors in patients with moderate or advanced hepatocellular carcinoma

Retrospective study of TACE combined immune checkpoint inhibitors in patients with moderate or advanced hepatocellular carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077108
Enrollment
Unknown
Registered
2023-10-31
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with moderate or advanced hepatocellular carcinoma

Interventions

TACE combined Tislelizumab:NA

Sponsors

the first Affiliated Hospital of Army Medical University,PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with unresectable moderate or advanced hepatocellular carcinoma; (2) Patients who received TACE combined Tislelizumab indirectly from August 1, 2020 to April 31, 2023 (=1 cycle of immunotherapy)

Exclusion criteria

Exclusion criteria: (1)Partial advanced/metastatic diseases have received treatment methods other than TACE/targeted/immune therapy (2) The interval between the first TACE treatment and immunotherapy exceeds 2 months (3) Patients who cannot be evaluated due to incomplete researcher evaluation data

Design outcomes

Primary

MeasureTime frame
objective response rate;—

Secondary

MeasureTime frame
disease control rate;progression-free survival;Overall survival;TACE treatment interval duration;—

Countries

China

Contacts

Public ContactZhang Hui

the first Affiliated Hospital of Army Medical University,PLA

825868773@qq.com+86 136 3791 2611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026